Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.67 |
| ▸ | DRD1 | P21728 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 8/20 | 0.64 |
| ▸ | CA9 | Q16790 | 7/20 | 0.64 |
| ▸ | CA1 | P00915 | 7/20 | 0.62 |
| ▸ | CA12 | O43570 | 5/20 | 0.62 |
| ▸ | PTPRC | P08575 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792751 | 0.85 | PTGS2 (0.58) | PTGS2PTGS1DRD1CA2CA9 | |
| SCHEMBL6732232 | 0.84 | PTGS2 (0.77) | PTGS2PTGS1DRD1CA2CA9 | |
| SCHEMBL6728102 | 0.83 | PTGS2 (0.67) | PTGS2PTGS1DRD1CA2CA9 | |
| SCHEMBL6725775 | 0.83 | CA2 (0.75) | PTGS2PTGS1DRD1CA2CA9 | |
| SCHEMBL6728058 | 0.83 | PTGS2 (0.62) | PTGS2PTGS1CA2CA9CA1 | |
| SCHEMBL2330330 | 0.83 | PTPRC (0.53) | PTGS2PTGS1DRD1CA2CA9 | |
| SCHEMBL7415919 | 0.83 | PTPRC (0.53) | PTGS2PTGS1DRD1CA2CA9 | |
| SCHEMBL6729369 | 0.82 | PTGS2 (0.76) | PTGS2PTGS1CA2CA9CA1 | |
| SCHEMBL6733291 | 0.82 | PTGS2 (0.73) | PTGS2PTGS1DRD1CA2CA9 | |
| SCHEMBL6725511 | 0.82 | PTGS2 (0.69) | PTGS2PTGS1DRD1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | claimed |
| US-7381728-B2 | Piperazine derivatives useful for the treatment of gastrointestinal disorders | GLAXO GROUP LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GLAXO GROUP LIMITED | 2007-11-08 | — | — | US | disclosed |
| US-7183320-B2 | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents | ELI LILLY AND COMPANY (US) | 2007-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GHSR, GHRHR, GIPR | PTGS2 558/4885PTGS1 467/4885DRD1 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.